|
시장보고서
상품코드
2008169
MR 백신 시장 : 백신 브랜드별, 유통 채널별, 지역별MR Vaccines Market, By Vaccine Brand (MR Vaccine, MRBEV (BE LTD.)), By Distribution Channel (Public, Private), By Geography (Commonwealth of Independent States (CIS) Countries, Latin America, Europe, Asia Pacific, Middle East, Africa) |
||||||
MR 백신 시장은 2026년에 7,200만 달러로 추정되고 있으며, 2033년까지 1억 160만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 2.1%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 7,200만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 2.10% | 예측 금액(2033년) | 1억 160만 달러 |
홍역-풍진 혼합(MR) 백신은 홍역 바이러스와 풍진 바이러스에 의한 감염을 예방하는 생백신입니다. 이 백신은 체내에 항바이러스 방어기전(항체)을 생성시켜 효과를 발휘합니다. 홍역(일명: 기침 홍역, 중증 홍역, 몰빌리, 홍역, 루베오라, 10일 홍역)은 전염성이 매우 강한 감염병입니다. 홍역에 감염되면 폐렴, 중이염, 부비동염, 경련(발작), 뇌손상, 사망 등 심각한 합병증을 유발할 수 있습니다. 성인과 5세 미만의 어린이는 심각한 합병증과 사망 위험이 높습니다. 임산부가 풍진(독일 홍역이라고도 함)에 감염되면 유산, 사산 또는 태아의 선천성 기형을 유발할 수 있습니다.
시장 역학
홍역 및 풍진 혼합(MR) 백신은 홍역 및 풍진에 대한 능동적 면역을 위한 피하주사로, 위험에 처한 청소년, 청소년, 소아 및 영아를 대상으로 합니다. 홍역 및 풍진(MR) 발생률 증가, MR 백신 개발을 위한 진행 중인 임상시험, 예방접종 서비스에 대한 인식 증가, 정부 주도의 예방접종 캠페인 증가, MR 백신 시장에서 활동하는 주요 기업이 WHO, UNICEF, GAVI Alliance와 같은 조직과의 제휴와 같은 비유기적 성장 전략의 채택 확대는 예측 기간 중 MR 백신 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다.
예를 들어 세계보건기구(WHO)에 따르면 2020년 1월부터 2021년 4월까지 아프리카 8개국에서 대규모 홍역 유행이 발생하여 예방접종 프로그램의 지연과 정기 예방접종 접종률이 낮아 수만 명의 어린이가 영향을 받았다고 합니다.
이 보고서의 주요 특징
- 세계의 MR 백신 시장에 대해 조사 분석했으며, 2020년을 기준연도로 하여 예측 기간(2021-2028년) 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트를 제공합니다.
- 세계의 MR 백신 시장의 주요 기업 개요을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 매개 변수를 기반으로 정리하여 수록하고 있습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계의 MR 백신 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 MR 백신 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 MR 백신 시장 : 백신 브랜드별(2026-2033년)
제5장 MR 백신 시장 : 유통 채널별(2026-2033년)
제6장 MR 백신 시장 : 지역별(2026-2033년)
제7장 경쟁 구도
제8장 섹션
KSA 26.05.04MR Vaccines Market is estimated to be valued at USD 72.0 Mn in 2026 and is expected to reach USD 101.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 2.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 72.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 2.10% | 2033 Value Projection: | USD 101.6 Mn |
Measles and rubella is a live virus vaccine that protects against infection with the measles and rubella viruses. It works by causing the body to produce its antiviral defenses (antibodies). Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and 10-day measles) is a highly contagious infectious disease. Measles infection can result in significant complications such as pneumonia, ear infections, sinus infections, convulsions (seizures), brain damage, and death. Adults and children under the age of 5 years are at a higher risk of serious complications and mortality. When pregnant women contract rubella (also known as German measles), it can result in miscarriages, stillbirths, or birth abnormalities in their unborn children.
Market Dynamics
Measles and Rubella (MR) vaccine is a subcutaneous injection for active immunization against Measles and Rubella in young adults, adolescents, children, and infants at risk. Increasing incidence of Measles and Rubella (MR), ongoing clinical trials to develop MR vaccines, growing awareness about immunization services, rising government initiatives to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are the major factors that are expected to drive growth of the MR vaccines market over the forecast period.
For instance, according to the World Health Organization (WHO), from January 2020 to April 2021, eight African nations experienced major measles outbreaks that affected tens of thousands of children, owing to delayed vaccination programs or low routine immunization coverage.
Key features of the study
- This report provides an in-depth analysis of the MR vaccines market, and provides market size (US$ Mn. and No. of Doses in Mn.), and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the MR vaccines market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The MR vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the MR vaccines market
Market Segmentation
- By Vaccine Brand
- MR Vaccine
- MRBEV (BE LTD.)
- By Distribution Channel
- Public
- Private
- By Region
- Commonwealth of Independent States (CIS) Countries
- Russia
- Uzbekistan
- Kazakhstan
- Ukraine
- Turkmenistan
- Belarus
- Armenia
- Latin America
- Brazil
- Argentina
- Mexico
- Honduras
- Colombia
- Peru
- Chile
- Europe
- Turkey
- Asia Pacific
- Pakistan
- Indonesia
- Bangladesh
- Philippines
- Vietnam
- Thailand
- Myanmar
- Malaysia
- Cambodia
- Nepal
- Sri Lanka
- Papua New Guinea
- Mauritius
- Middle East
- Israel
- UAE
- Iraq
- Iran
- Saudi Arabia
- Jordan
- Qatar
- Oman
- Syrian Arab Republic
- Africa
- South Africa
- Nigeria
- Tanzania
- Democratic Republic of Congo
- Ethiopia
- Kenya
- Egypt
- Morocco
- Ghana
- Uganda
- Burkina Faso
- Angola
- Algeria
- Zimbabwe
- Tunisia
- Botswana
- Libya
- Namibia
- Key Players
- PT Bio Farma
- Bio-Manguinhos
- BE Vaccines
- Serum Institute of India
- Crucell Switzerland AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Brand
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Therapy Assessment
- Disease Assessment
- Epidemiological Assessment
- Industry Assessment
4. MR Vaccines Market, By Vaccine Brand, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- MR Vaccine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- MRBEV (BE LTD.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
5. MR Vaccines Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
6. MR Vaccines Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Commonwealth of Independent States (CIS) Countries
- Market Size and Forecast, By Vaccine Brand, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Russia
- Uzbekistan
- Kazakhstan
- Ukraine
- Turkmenistan
- Belarus
- Armenia
- Latin America
- Market Size and Forecast, By Vaccine Brand, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Honduras
- Colombia
- Peru
- Chile
- Europe
- Market Size and Forecast, By Vaccine Brand, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Turkey
- Asia
- Market Size and Forecast, By Vaccine Brand, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Pakistan
- Indonesia
- Bangladesh
- Philippines
- Vietnam
- Thailand
- Myanmar
- Malaysia
- Cambodia
- Nepal
- Sri Lanka
- Papua New Guinea
- Mauritius
- Middle East
- Market Size and Forecast, By Vaccine Brand, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- UAE
- Israel
- Iraq
- Iran
- Saudi Arabia
- Jordan
- Qatar
- Oman
- Syrian Arab Republic
- Africa
- Market Size and Forecast, By Vaccine Brand, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Region/Country, 2026 - 2033, (USD Mn)
- Nigeria
- Tanzania
- Democratic Republic of Congo
- Ethiopia
- Kenya
- South Africa
- Egypt
- Morocco
- Ghana
- Uganda
- Burkina Faso
- Angola
- Algeria
- Zimbabwe
- Tunisia
- Botswana
- Libya
- Namibia
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- PT Bio Farma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bio-Manguinhos
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Crucell Switzerland AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Serum Institute of India
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BE Vaccines
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- PT Bio Farma
8. Section
- References
- Research Methodology
- About us and Sales Contact
